89 related articles for article (PubMed ID: 20035038)
1. Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).
Radin A; Marbury T; Osgood G; Belomestnov P
J Clin Pharmacol; 2010 Jul; 50(7):835-41. PubMed ID: 20035038
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
4. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
Vollmer T; Blight AR; Henney HR
Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
Hoffman HM; Throne ML; Amar NJ; Sebai M; Kivitz AJ; Kavanaugh A; Weinstein SP; Belomestnov P; Yancopoulos GD; Stahl N; Mellis SJ
Arthritis Rheum; 2008 Aug; 58(8):2443-52. PubMed ID: 18668535
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.
Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M
Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients.
Aramwit P; Supasyndh O; Sriboonruang T
J Clin Pharm Ther; 2008 Dec; 33(6):685-90. PubMed ID: 19138247
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects.
Klitgaard T; Nielsen JN; Skettrup MP; Harper A; Lange M
Growth Horm IGF Res; 2009 Dec; 19(6):463-70. PubMed ID: 19303337
[TBL] [Abstract][Full Text] [Related]
13. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
17. Rilonacept--CAPS and beyond.
Stahl N; Radin A; Mellis S
Ann N Y Acad Sci; 2009 Dec; 1182():124-34. PubMed ID: 20074281
[TBL] [Abstract][Full Text] [Related]
18. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
19. Plasma elimination of cardiac troponin I in end-stage renal disease.
Ellis K; Dreisbach AW; Lertora JL
South Med J; 2001 Oct; 94(10):993-6. PubMed ID: 11702827
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
Vollmer T; Henney HR
Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
